{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:23:24Z","timestamp":1793993004702,"version":"4.8.0"},"reference-count":12,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background\/Objectives: The DPYD gene encodes the enzyme dihydropyrimidine dehydrogenase that metabolizes fluoropyrimidines. Genetic variants in DPYD have been associated with altered enzyme activity; therefore, accurate detection and interpretation is critical for individualized fluoropyrimidine therapy. The most common causal variant is c.1129-5923C&gt;G (rs75017182) located in intron 10, which introduces a cryptic splice site. This variant is in high linkage disequilibrium (LD) in the HapB3 haplotype with a benign synonymous variant in exon 11, c.1236G&gt;A (rs56038477). Since c.1129-5923C&gt;G and c.1236G&gt;A have been reported in LD, many commercial kits use c.1236G&gt;A as a proxy for the function-altering intronic variant. Methods: A DPYD genotyping protocol was implemented following the quality regulations that apply to clinical laboratories (EN-ISO9001:2015 and EN-ISO15189:2022). NGS, MLPA and Sanger sequencing were used for validation purposes. Results: Over the last 5 years a total of 2007 patients have been analyzed at our department. The observed DPYD genotype frequencies aligned with those observed in European populations. Importantly, we have identified a patient harboring the c.1236G&gt;A variant, but in the absence of the c.1129-5923C&gt;G variant. This last result supports recently published findings suggesting that these two variants may not be in perfect LD, as previously assumed, and lead to suboptimal dosing for those patients carrying this allele. Finally, low frequency variants (c.496A&gt;G, c.2194G&gt;A, and c.1601G&gt;A), not described in DPYD analysis guidelines recommendations, were found in two patients who required fluoropyrimidines dose adjustment. Conclusions: These findings highlight the limitations of relying on proxy variants for clinical decision-making, as incomplete linkage disequilibrium may lead to misclassification of patients\u2019 metabolic capacity. Furthermore, in order to provide safer protocols for DPYD-based personalized treatment genetic panels should expand to include additional rare DPYD variants.<\/jats:p>","DOI":"10.3390\/genes17070741","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:58:04Z","timestamp":1782799084000},"page":"741","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2764-8507","authenticated-orcid":false,"given":"Josefa","family":"Salgado Garrido","sequence":"first","affiliation":[{"name":"Servicio de Gen\u00e9tica M\u00e9dica del Hospital Universitario de Navarra (HUN), 31008 Pamplona, Navarra, Spain"},{"name":"Departamento de Bioqu\u00edmica y Biolog\u00eda Molecular, Universidad P\u00fablica de Navarra (UPNA), 31006 Pamplona, Navarra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba","family":"Alonso Llorente","sequence":"additional","affiliation":[{"name":"Servicio de An\u00e1lisis Cl\u00ednicos del Hospital Universitari Arnau de Vilanova de Lleida, 25198 Lleida, Catalunya, Spain"},{"name":"IRBLleida, Institut de Recerca Biom\u00e8dica de Lleida Fundaci\u00f3 Dr. Pifarre, 25198 Lleida, Catalunya, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4600-6972","authenticated-orcid":false,"given":"Oscar","family":"Teijido Hermida","sequence":"additional","affiliation":[{"name":"Departamento de Ciencias de la Salud, Universidad P\u00fablica de Navarra (UPNA), 31006 Pamplona, Navarra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1290-4050","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Beloqui Lizaso","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia del Hospital Universitario de Navarra (HUN), 31008 Pamplona, Navarra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Gr\u00e1ndez Ladr\u00f3n de Guevara","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda M\u00e9dica del Hospital Reina Sof\u00eda de Tudela, 31500 Tudela, Navarra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Mata","family":"Velasco","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda del Hospital Universitario de Navarra (HUN), 31008 Pamplona, Navarra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Vera Garc\u00eda","sequence":"additional","affiliation":[{"name":"Servicio de Oncolog\u00eda del Hospital Universitario de Navarra (HUN), 31008 Pamplona, Navarra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Valiente Mart\u00edn","sequence":"additional","affiliation":[{"name":"Servicio de Gen\u00e9tica M\u00e9dica del Hospital Universitario de Navarra (HUN), 31008 Pamplona, Navarra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s12094-021-02708-4","article-title":"Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines","volume":"24","author":"Salazar","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/OP.20.00553","article-title":"All You Need to Know About DPYD Genetic Testing for Patients Treated with Fluorouracil and Capecitabine: A Practitioner-Friendly Guide","volume":"16","author":"Innocenti","year":"2020","journal-title":"JCO Oncol. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107447","DOI":"10.1016\/j.pharmthera.2019.107447","article-title":"5-fuorouracil and other fuoropyrimidines in colorectal cancer: Past, present and future","volume":"206","author":"Vodenkova","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1517\/14740338.2010.511610","article-title":"Safety of capecitabine: A review","volume":"9","author":"Mikhail","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jmoldx.2024.05.015","article-title":"DPYD Genotyping Recommendations","volume":"26","author":"Pratt","year":"2024","journal-title":"J. Mol. Diagn."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_7","first-page":"1603","article-title":"Ethnic Diversity of DPD Activity and the DPYD Gene: Review of the Literature","volume":"14","author":"White","year":"2021","journal-title":"Pharmgenomics Pers. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/phar.2463","article-title":"DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation","volume":"40","author":"Varughese","year":"2020","journal-title":"Pharmacotherapy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ijc.29025","article-title":"Clinical Importance of Risk Variants in the Dihydropyrimidine Dehydrogenase Gene for the Prediction of Early-onset Fluoropyrimidine Toxicity","volume":"136","author":"Froehlich","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/bioinformatics\/btv402","article-title":"LDlink: A Web-based Application for Exploring Population-specific Haplotype Structure and Linking Correlated Alleles of Possible Functional Variants","volume":"31","author":"Machiela","year":"2015","journal-title":"Bioinformatics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e13699","DOI":"10.1111\/cts.13699","article-title":"Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing","volume":"17","author":"Turner","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/bcp.15144","article-title":"DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols","volume":"88","author":"Bozina","year":"2022","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/7\/741\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:14:03Z","timestamp":1783599243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/17\/7\/741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":12,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["genes17070741"],"URL":"https:\/\/doi.org\/10.3390\/genes17070741","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]}}}